+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06605404

Molecular Residual Disease Study in Selected Solid Tumors Collecting Clinical Data and Biospecimens

Led by Paradigm Health · Updated on 2026-09-24

1350

Participants Needed

47

Research Sites

17 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are collecting clinical data and biological samples from adults diagnosed with stage I, stage II, or operable stage III cancers in certain solid tumor types. This observational study aims to help develop tests that improve cancer detection and assess the risk of cancer returning. Participants continue to receive standard care from their own doctors throughout the study. Participants will provide blood and tumor tissue samples during their routine care. The study includes several tumor groups such as bladder cancer, esophageal cancer, gastric and gastroesophageal junction cancer, melanoma, non-small cell lung cancer, pancreatic cancer, and a mix of other solid tumors. Enrollment occurs either before or within three months after surgery, and no prior systemic therapy for the current cancer is allowed before joining. During the approximately five and a half years of involvement, participants will be observed with collection of blood and tissue samples as part of a biospecimen registry. Researchers will use this information to study molecular residual disease in solid tumors. All clinical data and samples will be gathered under routine care settings, with no additional treatment provided by the study team.

CONDITIONS

Brief Title

Pan-tumor MRD Study

Research Team

A

Anosheh Afghahi, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here